On 3 February 2023, the US-FDA approved the ADC drug sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.)for the therapy of patients with unresectable locally advanced or metastatic hormone-receptor-positive (HR+), and HER2- metastatic breast cancer patients who received endocrine-based therapy and at least two more systemic therapies for metastatic disease. The gene discussed is ERBB2; the disease is metastatic neoplasm.